Last C$2.48 CAD
Change Today 0.00 / 0.00%
Volume 103.6K
NTB On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
Toronto
As of 3:59 PM 07/21/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Xavier Harland BSc Act, CFA, FRM

Former Chief Financial Officer of Acasti Pharma, Neptune Technologies & Bioressources, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

--C$109,223
As of Fiscal Year 2014

Background*

Mr. Xavier Harland, BSc Act, CFA, FRM, served as the Chief Financial Officer of Acasti Pharma Inc. from March 21, 2011 to June 16, 2014. Mr. Harland served as a Director of Finance at Neptune Technologies & Bioresources, Inc. since 2004. Mr. Harland is an actuary, a Chartered Financial Analyst (“CFA”) charterholder and Financial Risk Manager (“FRM”) holder. He graduated in Actuarial Science from Laval University in 2003.

Corporate Headquarters*

545 Promenade du Centropolis
Laval, Quebec H7T 0A3

Canada

Phone: 450-687-2262
Fax: 450-687-2272

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

Unknown/Other Education 2003
Université Laval

Other Affiliations*

Annual Compensation*

SalaryC$23,139
Total Annual CompensationC$23,139

Stock Options*

Restricted Stock AwardsC$69,000
Total Value of OptionsC$18,500
Total Number of Options200,000

Total Compensation*

Total Annual Cash CompensationC$23,139
Total Short Term CompensationC$23,139
Other Long Term CompensationC$69,000
Total Calculated CompensationC$109,223
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NTB:CN C$2.48 CAD 0.00

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Philip C. Mezey Chief Executive Officer, President and Director
Itron, Inc.
$800.0K
Richard A. Meeusen Chairman, Chief Executive Officer and President
Badger Meter Inc.
$587.1K
Ariel Katz Chief Executive Officer and President
Enzymotec Ltd.
--
William E. Shell M.D.Chairman of The Board, Chief Executive Officer, Chief Scientific Officer and Member of Scientific Advisory Committee
Targeted Medical Pharma, Inc.
$476.2K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEPTUNE TECH & BIORESSOURCES, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.